)
Overview
<ul>
<li>Nutex Health Q3 revenue grows 239.9% yr/yr, beating analyst expectations</li>
<li>Net income for Q3 2025 at $55.4 mln, reversing loss from Q3 2024</li>
<li>Company regains Nasdaq compliance following timely filing of reports</li>
</ul>
Outlook
<ul>
<li>Company did not provide specific future guidance</li>
</ul>
Result Drivers
<ul>
<li>HOSPITAL REVENUE - Hospital division revenue increased 262.8% driven by higher acuity claims and IDR process success</li>
<li>ARBITRATION COSTS - Arbitration costs approximated 24-26% of arbitration-related revenue due to underpayment from payors</li>
<li>STOCK-BASED COMPENSATION - Stock-based compensation expenses increased due to obligations for under-construction hospitals</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Beat $267.8 $213.81
Revenue mln mln (3
Analysts
)
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>Wall Street’s median 12-month price target for Nutex Health Inc is $220.00, about 54.9% above its November 18 closing price of $99.20</li>
<li>The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 8 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

NUTX

Nutex Health's Q3 revenue grew 239.9% year-over-year, beating analyst expectations with $267.8 million. The company reported a net income of $55.4 million, reversing a loss from Q3 2024, and regained Nasdaq compliance. Hospital division revenue increased 262.8%. The stock has a median 12-month price target of $220.00, 54.9% above its recent closing price. The current analyst rating is 'buy'.

Nutex Health Q3 revenue beats expectations